.svg){kind=small}
Oct-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Is this your brand?
See your full sales and distribution data: where you sell, how you're priced, and how you rank against the brands next to you on the shelf.
See your brand's dataCarry this brand in your store?
Headset Retailer is free. Connect your POS and see what's selling and what's sitting.
Sign up freeMarket Insights Snapshot
In October 2026, Canna Clinicals concentrated 83.55% of sales in Tincture & Sublingual, where category sales rose 19.97% year over year and 11.47% month over month, while the brand’s average price fell 26.08% YoY. Topical expanded to a 10.63% share with a 30.91% MoM increase, whereas Capsules contracted to 5.82% share with a 43.96% YoY decline and a 21.82% MoM drop. With Tincture & Sublingual positioned at rank 6 in New York, the mix shift toward formats aligned with that ranking and away from Capsules implies the brand is leaning into higher-velocity sublingual products while deprioritizing capsule SKUs that are losing momentum.
The simultaneous 24.96% YoY brand sales lift alongside a 26.08% YoY average price decrease suggests volume-led gains concentrated in Tincture & Sublingual (up 19.97% YoY, 11.47% MoM) and supported by Topical’s MoM surge (30.91%), while Capsules’ double-digit retrenchment (-43.96% YoY, -21.82% MoM) trims breadth. Holding rank 6 in New York within Tincture & Sublingual indicates mid-pack visibility; the mix and pricing trajectory imply a push for share capture via price-accessible sublinguals and selective investment in Topicals to diversify, accepting near-term rank trade-offs in Capsules.
Competitive Landscape
Canna Clinicals ranks #6 in New York Tincture & Sublingual in October 2026, improving 3 positions year over year from #9 while edging up 1 place from #7 three months prior; this marks a peak rank of #6 in October 2026 and situates the brand one slot behind OMO - Open Minded Organics at #5, which rose 1 place from #6 year over year despite a -9.7% sales change. At the top of the set, Ayrloom held #1 with a 0-position YoY change and +3.6% sales growth, while Mfny (Marijuana Farms New York) slid from #3 to #4 alongside a -34.9% sales decline, indicating that Canna Clinicals’ upward rank shift is occurring in a reshuffling tier where stability at #1 coexists with contraction and churn below, implying the brand’s current trajectory positions it to contest the #5 spot next if it sustains incremental share gains.
Notable Products
Canna Clinicals is highly concentrated in one item in October 2026, with CBD/THC 1:10 Max Strength Tincture accounting for 65.4% of sales and the Tincture segment at 83.5% of the lineup. That level of focus means most of its sales come from tinctures, led by a single product.
Peer avg: average price of the same product type and package size in the same states that month.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
